Valbiotis
Develops clinically proven, plant-based supplements for metabolic diseases.
ALVAL | PA
Overview
Corporate Details
- ISIN(s):
- FR0013254851
- LEI:
- 969500VP4JBJCF0MOP60
- Country:
- France
- Address:
- RUE PAUL VATINE, 17180 PERIGNY
- Website:
- https://www.valbiotis.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of other food products
Description
Valbiotis is a research and development company that develops and commercializes plant-based dietary supplements for the prevention and management of metabolic diseases. The company's portfolio is centered on its patented "TOTUM" line of active substances, which undergo rigorous clinical trials to validate their efficacy. Key products include TOTUM•63 for reducing blood glucose in prediabetic individuals, TOTUM•448 for cardio-liver health, and TOTUM•854 for managing blood pressure. Valbiotis provides scientifically proven, natural, non-drug solutions and is transitioning from a research-focused model to a commercial-stage enterprise.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-04-11 17:40 |
Rapport complémentaire du Directoire à l'AGM du 02/05/2023
|
French | 243.9 KB | ||
| 2023-03-15 17:40 |
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 760.8 KB | ||
| 2023-03-15 17:40 |
Inside Information / News release on accounts, results
|
English | 759.5 KB | ||
| 2023-03-13 17:40 |
Informations privilégiées / Autres communiqués
|
French | 520.2 KB | ||
| 2023-03-13 17:40 |
Inside Information / Other news releases
|
English | 514.1 KB | ||
| 2023-02-23 17:40 |
Inside Information / Other news releases
|
English | 486.0 KB | ||
| 2023-02-23 17:40 |
Informations privilégiées / Autres communiqués
|
French | 486.9 KB | ||
| 2023-01-31 17:40 |
Acquisition ou cession des actions de l'émetteur / Information relative au cont…
|
French | 488.4 KB | ||
| 2023-01-30 17:40 |
Informations privilégiées / Autres communiqués
|
French | 459.3 KB | ||
| 2023-01-30 17:40 |
Inside Information / Other news releases
|
English | 455.2 KB | ||
| 2023-01-10 07:35 |
Inside Information / Other news releases
|
English | 445.9 KB | ||
| 2023-01-10 07:35 |
Informations privilégiées / Autres communiqués
|
French | 458.9 KB | ||
| 2022-12-14 17:40 |
Inside Information / Other news releases
|
English | 914.5 KB | ||
| 2022-12-14 17:40 |
Informations privilégiées / Autres communiqués
|
French | 913.7 KB | ||
| 2022-11-09 08:30 |
Valbiotis réalise avec succès une levée de fonds d’un montant de 9,7 millions d…
|
French | 1.0 MB |
Automate Your Workflow. Get a real-time feed of all Valbiotis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valbiotis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valbiotis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-01-17 | N/A | Other | Other | 10,400 | 46,072.00 EUR |
Peer Companies
